{"id":41420,"date":"2025-09-15T16:43:52","date_gmt":"2025-09-15T08:43:52","guid":{"rendered":"https:\/\/flcube.com\/?p=41420"},"modified":"2025-09-15T16:43:52","modified_gmt":"2025-09-15T08:43:52","slug":"cspc-pharmaceutical-group-secures-nmpa-approval-for-syh2066-in-rsv-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41420","title":{"rendered":"CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials"},"content":{"rendered":"\n<p><strong>CSPC Pharmaceutical Group Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/1093:HKG\">HKG: 1093<\/a>)<\/strong> announced that its novel oral small\u2011molecule, <strong>SYH2066<\/strong>, has been granted <strong>clinical\u2011trial approval<\/strong> by the <strong>National Medical Products Administration (NMPA)<\/strong> for the treatment of <strong>respiratory tract infections caused by Respiratory Syncytial Virus (RSV)<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-what-sets-syh2066-apart\">What Sets SYH2066 Apart?<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class\u202f1 New Chemical Entity<\/strong> \u2013 Developed entirely in\u2011house, SYH2066 is a first\u2011in\u2011class oral agent that directly targets RSV replication.<\/li>\n\n\n\n<li><strong>Favorable Pharmacokinetics<\/strong> \u2013 Pre\u2011clinical studies demonstrate high oral bioavailability and a robust pharmacokinetic profile, ensuring efficient systemic exposure upon oral dosing.<\/li>\n\n\n\n<li><strong>Potent Antiviral Activity<\/strong> \u2013 In animal disease models, SYH2066 markedly reduced RSV viral load, showcasing its therapeutic potential in a rapidly growing market for RSV therapeutics.<\/li>\n\n\n\n<li><strong>High Safety Margin<\/strong> \u2013 Toxicology panels revealed an excellent safety profile, with no significant off\u2011target effects observed in multiple pre\u2011clinical species.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-regulatory-milestone-and-market-implications\">Regulatory Milestone and Market Implications<\/h3>\n\n\n\n<p>The NMPA\u2019s approval places SYH2066 among the first orally administrable RSV candidates to enter Phase\u202fI\u2011III clinical development in China. This is a strategic win for CSPC, positioning the company at the forefront of RSV treatment\u2014a disease burden that accounts for millions of hospitalizations annually, especially in infants and the elderly.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-next-steps\">Next Steps<\/h3>\n\n\n\n<p>CSPC plans to initiate a Phase\u202fI dose\u2011escalation study in healthy volunteers within the next 60\u202fdays, followed by a Phase\u202fII study in RSV\u2011positive adults. Successful outcomes could accelerate a global launch, addressing a critical unmet need in respiratory infectious diseases.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2025091201127_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025091201127_c.\"><\/object><a id=\"wp-block-file--media-bf17b65f-e901-43e1-9f93-b833d8de6d48\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2025091201127_c.pdf\">2025091201127_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2025091201127_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-bf17b65f-e901-43e1-9f93-b833d8de6d48\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its novel oral small\u2011molecule, SYH2066, has been&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41423,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,171,855],"class_list":["post-41420","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-cspc-pharmaceutical","tag-hkg-1093"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its novel oral small\u2011molecule, SYH2066, has been granted clinical\u2011trial approval by the National Medical Products Administration (NMPA) for the treatment of respiratory tract infections caused by Respiratory Syncytial Virus (RSV).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41420\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its novel oral small\u2011molecule, SYH2066, has been granted clinical\u2011trial approval by the National Medical Products Administration (NMPA) for the treatment of respiratory tract infections caused by Respiratory Syncytial Virus (RSV).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41420\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-15T08:43:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1509.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41420#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41420\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials\",\"datePublished\":\"2025-09-15T08:43:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41420\"},\"wordCount\":253,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41420#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1509.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CSPC Pharmaceutical\",\"HKG: 1093\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41420#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41420\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41420\",\"name\":\"CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41420#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41420#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1509.webp\",\"datePublished\":\"2025-09-15T08:43:52+00:00\",\"description\":\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its novel oral small\u2011molecule, SYH2066, has been granted clinical\u2011trial approval by the National Medical Products Administration (NMPA) for the treatment of respiratory tract infections caused by Respiratory Syncytial Virus (RSV).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41420#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41420\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41420#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1509.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1509.webp\",\"width\":1080,\"height\":608,\"caption\":\"CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41420#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its novel oral small\u2011molecule, SYH2066, has been granted clinical\u2011trial approval by the National Medical Products Administration (NMPA) for the treatment of respiratory tract infections caused by Respiratory Syncytial Virus (RSV).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41420","og_locale":"en_US","og_type":"article","og_title":"CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials","og_description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its novel oral small\u2011molecule, SYH2066, has been granted clinical\u2011trial approval by the National Medical Products Administration (NMPA) for the treatment of respiratory tract infections caused by Respiratory Syncytial Virus (RSV).","og_url":"https:\/\/flcube.com\/?p=41420","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-15T08:43:52+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1509.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41420#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41420"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials","datePublished":"2025-09-15T08:43:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41420"},"wordCount":253,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41420#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1509.webp","keywords":["Clinical trial approval \/ initiation","CSPC Pharmaceutical","HKG: 1093"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41420#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41420","url":"https:\/\/flcube.com\/?p=41420","name":"CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41420#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41420#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1509.webp","datePublished":"2025-09-15T08:43:52+00:00","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its novel oral small\u2011molecule, SYH2066, has been granted clinical\u2011trial approval by the National Medical Products Administration (NMPA) for the treatment of respiratory tract infections caused by Respiratory Syncytial Virus (RSV).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41420#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41420"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41420#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1509.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1509.webp","width":1080,"height":608,"caption":"CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41420#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1509.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41420"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41420\/revisions"}],"predecessor-version":[{"id":41424,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41420\/revisions\/41424"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41423"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}